- In June 2024, Geron Corporation recently announced that the FDA has granted approval for Rytelo (imetelstat) for use in patients with lower- to intermediate-risk myelodysplastic syndromes, a category of blood cancers characterized by improperly formed or dysfunctional blood cells
- In August 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for treating anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who have not previously used erythropoiesis-stimulating agents and may need regular red blood cell (RBC) transfusions
- In September 2021, Merck, known as MSD outside the U.S. and Canada, and Acceleron Pharma Inc., a publicly traded biopharmaceutical company, have entered into a definitive agreement in which Merck, through a subsidiary, will acquire Acceleron for USD 180 per share in cash, valuing the company at approximately USD 11.5 billion. Acceleron’s portfolio includes REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, Canada, and Australia for the treatment of anemia in specific rare blood disorders
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Reblozyl and Others), Strength (25mg, 75mg, and Others), Application (Anemia due to Beta-thalassemia and Anemia with Myelodysplastic syndrome (MDS)), Dosage (Injection, Powder, and Others), Route of Administration (Subcutaneous and Other), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Erythroid Maturation Agent Market size was valued at USD 971.20 USD Million in 2023.
The Global Erythroid Maturation Agent Market is projected to grow at a CAGR of 9.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
